Cargando…

Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report

Linear IgA bullous dermatosis (LABD) is a rare, idiopathic, or drug-induced vesiculobullous disease caused by IgA autoantibodies in the basement membrane zone. An 84-year-old man was started on spironolactone two weeks before presentation for the management of hypertension and heart failure with pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Philip, Vineetha, Ogunleye, Olushola O, Chukwu, Nneka, Rosenblum, Isaac, Collins, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358603/
https://www.ncbi.nlm.nih.gov/pubmed/37485225
http://dx.doi.org/10.7759/cureus.40690
_version_ 1785075700269580288
author Philip, Vineetha
Ogunleye, Olushola O
Chukwu, Nneka
Rosenblum, Isaac
Collins, Susan
author_facet Philip, Vineetha
Ogunleye, Olushola O
Chukwu, Nneka
Rosenblum, Isaac
Collins, Susan
author_sort Philip, Vineetha
collection PubMed
description Linear IgA bullous dermatosis (LABD) is a rare, idiopathic, or drug-induced vesiculobullous disease caused by IgA autoantibodies in the basement membrane zone. An 84-year-old man was started on spironolactone two weeks before presentation for the management of hypertension and heart failure with preserved ejection fraction. He presented to our hospital for evaluation of worsening lower extremity swelling and a painful pruritic rash that started on the day preceding his presentation. On examination, he had 3+ lower extremity edema and an erythematous, painful, pruritic, bullous rash on all his extremities. He had a significantly elevated IgA level (1033 mg/dL). A lesional skin biopsy demonstrated epidermal ulceration with degenerated collagen fibers. Direct immunofluorescence of the perilesional skin showed linear IgA at the dermal-epidermal junction. The rash resolved following steroid therapy and discontinuation of spironolactone. There have been previous reports of bullous pemphigoid induced by spironolactone. To our knowledge, LABD associated with spironolactone has not previously been reported.
format Online
Article
Text
id pubmed-10358603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103586032023-07-21 Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report Philip, Vineetha Ogunleye, Olushola O Chukwu, Nneka Rosenblum, Isaac Collins, Susan Cureus Dermatology Linear IgA bullous dermatosis (LABD) is a rare, idiopathic, or drug-induced vesiculobullous disease caused by IgA autoantibodies in the basement membrane zone. An 84-year-old man was started on spironolactone two weeks before presentation for the management of hypertension and heart failure with preserved ejection fraction. He presented to our hospital for evaluation of worsening lower extremity swelling and a painful pruritic rash that started on the day preceding his presentation. On examination, he had 3+ lower extremity edema and an erythematous, painful, pruritic, bullous rash on all his extremities. He had a significantly elevated IgA level (1033 mg/dL). A lesional skin biopsy demonstrated epidermal ulceration with degenerated collagen fibers. Direct immunofluorescence of the perilesional skin showed linear IgA at the dermal-epidermal junction. The rash resolved following steroid therapy and discontinuation of spironolactone. There have been previous reports of bullous pemphigoid induced by spironolactone. To our knowledge, LABD associated with spironolactone has not previously been reported. Cureus 2023-06-20 /pmc/articles/PMC10358603/ /pubmed/37485225 http://dx.doi.org/10.7759/cureus.40690 Text en Copyright © 2023, Philip et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Philip, Vineetha
Ogunleye, Olushola O
Chukwu, Nneka
Rosenblum, Isaac
Collins, Susan
Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title_full Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title_fullStr Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title_full_unstemmed Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title_short Linear IgA Bullous Dermatosis Attributable to the Use of Spironolactone: A Case Report
title_sort linear iga bullous dermatosis attributable to the use of spironolactone: a case report
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358603/
https://www.ncbi.nlm.nih.gov/pubmed/37485225
http://dx.doi.org/10.7759/cureus.40690
work_keys_str_mv AT philipvineetha linearigabullousdermatosisattributabletotheuseofspironolactoneacasereport
AT ogunleyeolusholao linearigabullousdermatosisattributabletotheuseofspironolactoneacasereport
AT chukwunneka linearigabullousdermatosisattributabletotheuseofspironolactoneacasereport
AT rosenblumisaac linearigabullousdermatosisattributabletotheuseofspironolactoneacasereport
AT collinssusan linearigabullousdermatosisattributabletotheuseofspironolactoneacasereport